$11.55
5.67% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US19240Q2012
Symbol
COGT

Cogent Biosciences Inc Stock price

$11.55
+0.46 4.15% 1M
+3.41 41.89% 6M
+3.75 48.08% YTD
+3.05 35.88% 1Y
-2.58 18.26% 3Y
+2.19 23.40% 5Y
-32.89 74.01% 10Y
-32.89 74.01% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.62 5.67%
ISIN
US19240Q2012
Symbol
COGT
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.3b
Net debt
positive
Cash
$237.9m
Shares outstanding
113.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.9
Financial Health
Equity Ratio
78.2%
Return on Equity
-78.4%
ROCE
-138.5%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-297.1m | $-288.3m
EBIT
$-299.7m | $-295.5m
Net Income
$-204.5m | $-245.9m
Free Cash Flow
$-234.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-23.1% | -5.4%
EBIT
-22.9% | -7.1%
Net Income
4.8% | -22.4%
Free Cash Flow
-32.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.8
FCF per Share
$-2.1
Short interest
11.2%
Employees
205
Rev per Employee
$0.0
Show more

Is Cogent Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Cogent Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Cogent Biosciences Inc forecast:

14x Buy
78%
4x Hold
22%

Analyst Opinions

18 Analysts have issued a Cogent Biosciences Inc forecast:

Buy
78%
Hold
22%

Financial data from Cogent Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
26% 26%
-
- Research and Development Expense 251 251
22% 22%
-
-297 -297
23% 23%
-
- Depreciation and Amortization 2.54 2.54
6% 6%
-
EBIT (Operating Income) EBIT -300 -300
23% 23%
-
Net Profit -204 -204
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cogent Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cogent Biosciences Inc Stock News

Neutral
GlobeNewsWire
8 days ago
Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints On track to share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025 $453 million in pro-forma cash sufficient to fund operations through anticipated launch and into 2027; i...
Positive
24/7 Wall Street
21 days ago
Insider buying has been slow this month, as buy windows close ahead of the new earnings-reporting season.
Neutral
GlobeNewsWire
about one month ago
WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its previously announced upsized underwritten public offering of 25,555,556 shares of its common stock, which includes 3,333,333 shares issued pursuant to t...
More Cogent Biosciences Inc News

Company Profile

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Robbins
Employees 205
Founded 2014
Website www.cogentbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today